The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Sequencing BCMA-targeted agents in multiple myeloma
Salomon Manier, MD, PhD, Lille University, Lille, France, discusses the feasibility and efficacy of sequencing BCMA-targeted agents in multiple myeloma. Whilst it has been shown that it is possible to sequence BCMA-targeted agents, response rates (RR) are lower when patients that have been exposed to an anti-BCMA agent are treated with a second BCMA-targeted drug. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
